SUMMARY The capacity of monocytes from patients with rheumatoid arthritis to generate superoxide anion in vitro after stimulation with serum treated zymosan (STZ) or IgG treated zymosan (IgTZ) was studied before and during therapy with penicillamine (n=9) or sodium aurothiomalate (AuTM) (n=12). Significant increases in rates of STZ (p<0-01) and IgTZ (p<002) stimulated superoxide anion production were seen after successful therapy (14 patients), which were paralleled by a significant increase in serum thiol levels. Patients who did not respond clinically to therapy (n=4) showed a smaller mean increase in serum thiol levels and had high mean rates of in vitro superoxide production before and after second-line therapy. Three patients were withdrawn from the study. The data suggest that successful therapy with penicillamine or AuTM may be associated with monocyte activation, and possible mechanisms are discussed.
gocytic cells will respond with a burst of oxygen consumption and oxygen free radical release to a number of soluble and particulate stimuli, includinC 5a and immune complexes,6 opsonised organisms, and non-immune stimuli such as phorbol myristate acetate,8 formyl-methionyl tripeptides,9 and fluoride ion. 10 Since rheumatoid synovium contains numerous marrow derived mononuclear phagocytes,"' the capacity of these cells to generate oxygen free radicals and the influence of antirheumatic therapy on this function is of some interest.
It has been suggested that the mechanism of action of drugs such as sodium aurothiomalate (AuTM) and penicillamine may include both a free radical scavenging effect12 and possibly an inhibitory effect on oxygen free radical release by phagocytes.'3 Similar observations have been made concerning non-steroidal anti-inflammatory drugs (NSAIDs).14 15 However, in a previous study of monocyte superoxide anion production '6 duration of EMS and a global assessment of the patients response to therapy (better, worse, or no change).
The success or failure of therapy was judged by a composite clinical score based on change in EMS, ESR, and a global assessment of response to therapy (Table 1) . A total score of + 1 or more was judged a response and 0 or less a failure. Each individual study was terminated when the patient was judged to have responded or had received six months' therapy without improvement. Three patients were withdrawn from the study; one patient on penicillamine did not wish to continue participating after 10 weeks, two patients on AuTM developed rashes necessitating withdrawal of therapy. The experimental data on these three patients are presented separately.
Students' t test, either paired or unpaired, was used for statistical comparisons wherever appropriate.
Results

CLINICAL STUDIES
There was no significant difference in disease activity between the responders and non-responders before therapy as judged by duration of early morning stiffness (EMS) or erythrocyte sedimentation rate (ESR) ( Table 2 ). All patients were strongly seropositive for rheumatoid factor (RF), except for one non-responder who was seronegative. All patients continued with the same NSAID therapy during the period of study. Responders to second-line therapy showed significant falls in ESR and log titre of rheumatoid factor and improvement in clinical score; the number of non-responders is too small for statistical analysis, but these subjects showed no fall in ESR or log titre of rheumatoid factor and a deterioration in clinical score ( Fig. 1 ). There was no significant difference in rates of stimulated monocyte superoxide anion production between normal controls or responders to secondline therapy before starting treatment. However, after therapy a significant rise was seen in rates of superoxide release by monocytes from 'responders' when stimulated with either STZ (p<0-01) or IgTZ (p<0-02). The number of non-responders is too small for statistical analysis, but it can be seen that the mean rate of superoxide release by monocytes from the four non-responders was high both before and after therapy (Fig. 2) .
Levels of serum thiols in responders were significantly lower than those of controls before therapy (p<O-Ol) and rose significantly (p<O.Ol) after therapy to normal levels. The changes are thus concordant with superoxide production by monocytes from responders. In two of the four non-responders levels of serum thiols were essentially unchanged after therapy, while in the other two a rise in thiols was seen. The mean increase in serum thiols in nonresponders (50 gM) was half that of the responders (100 gM) (Fig. 2) .
WITHDRAWALS FROM STUDY
Three patients withdrew from the study.
Patient A declined to participate in the study after 10 weeks of therapy but none the less wished to continue penicillamine. By the 10th week a sharp rise in serum thiols and rates of stimulated superoxide release had occurred, but it was not clear at that stage whether the patient was responding clinically to penicillamine therapy. At (Fig. 3) .
Patient B developed a skin rash after 230 mg of AuTM and was started on hydroxychloroquine 400 mg/day by her attending physician; the latter drug was introduced four days before the second measurement of superoxide anion generation. Serum thiol levels and rates of superoxide release fell in this patient (Fig. 3) .
Patient C developed a skin rash on treatment with AuTM. Only pretreatment values of serum thiols and superoxide production are available (Fig. 3) .
Discussion
We have previously found16 that monocytes from RA patients on second-line therapy unexpectedly showed enhanced superoxide release in response to opsonised zymosan compared with normal controls or patients on NSAIDs alone. Although the effect did not appear to be due to increased disease activity, this possibility could not be satisfactorily excluded. No increase was seen in response to fluoride ion, a biochemical stimulus which does not involve membrane receptors, and it therefore seemed likely that surface receptors which bind opsonised zymosan were involved in mediating the increased superoxide release. No differences were found either in basal unstimulated levels of superoxide production or in levels of 'non-dismutase inhibitable' reducing activity (i.e. cytochrome c reduction not attributable to superoxide anion). Furthermore AuTM and penicillamine had no enhancing effect on monocyte superoxide production in vitro (unpublished observations), suggesting that the mechanism of the in vivo effect is indirect.
The results we now report confirm that the capacity of blood monocytes to generate superoxide anion in response to zymosan opsonised with serum or IgG increases during successful therapy with AuTM or penicillamine and is not related to increased disease activity. Furthermore, this increase is accompanied by a rise in serum free thiol levels. An identical pattern was seen after one month in one of the patients who withdrew from the experimental part of the study, but continued with and later responded to penicillamine treatment. Although the number of 'non-responders' is small, the data suggest that monocytes from these individuals behave differently. there is a correlation between macrophage activation and the immune status of the host. Thus changes in activation of mononuclear phagocytes and their capacity for oxygen free radical generation may also reflect alterations in the immunological spectrum of RA which accompany therapy with drugs such as penicillamine.42
In conclusion our data confirm that penicillamine and gold therapy in RA enhances receptor mediated superoxide generation by monocytes, though the mechanism is not clear. These observations raise important questions about the inflammatory and immunoregulatory role of superoxide anion during the rheumatoid process. Studies are now in progress to determine whether enhanced superoxide release reflects biochemical or immunological mechanisms or possibly both. 
